Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model
Authors:
- Olivier RenéOROlivier René
- Manuel SaldiviaMSManuel Saldivia
- Maxime DauphinaisMDMaxime Dauphinais
- Lei ZhangLZLei Zhang
- Scott A. HollingsworthSHScott A. Hollingsworth
- Jan JiricekJJJan Jiricek
- Dennis C. KoesterDKDennis C. Koester
- Sarah L. MillerSMSarah L. Miller
- Sarah L. WilliamsSWSarah L. Williams
- Pearly S. NgPNPearly S. Ng
- Debjani PatraDPDebjani Patra
- Rajiv S. JumaniRJRajiv S. Jumani
Open Access
- 7 January 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1135-1153
Abstract
Chagas Disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi, affecting millions worldwide. Current treatments suffer from variable efficacy, long duration, and safety concerns, highlighting the need for better therapies. A phenotypic screening of the Novartis compound library against Trypanosoma brucei identified cyanotriazole (CT) compounds with rapid sterilizing activity across kinetoplastids via selective inhibition of parasite topoisomerase II. First-generation CTs had safety liabilities, including lymphopenia and neutrophilia due to sphingolipid pathway modulation. Medicinal chemistry optimization led to a tailored aminopyrrolidine core structure for Chagas Disease, improving ADME properties and reducing off-target effects. IID432 showed potent activity against T. cruzi (EC50 = 8 nM) and achieved a relapse-free cure in a chronic mouse model of infection with shorter treatment duration. These findings support IID432 as a promising fast-acting, curative therapy for T. cruzi infections.Keywords
Funding Information
- Wellcome Trust (219639/Z/19/Z)
- Innovation in 3Rs
This publication has 46 references indexed in Scilit:
- A promising pipeline of preclinical drug candidates for leishmaniasis and chronic Chagas’ diseaseTrends in Parasitology, 2024
- The expanding repertoire of covalent warheads for drug discoveryDrug Discovery Today, 2023
- Chagas diseaseThe Lancet, 2018
- Cellular assay for the characterization of sphingosine-1-phosphate lyase inhibitorsAnalytical Biochemistry, 2013
- Drug–DNA Intercalation2013
- Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and functionAdvances in Enzyme Regulation, 2010
- Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein BindingJournal of Pharmaceutical Sciences, 2008
- The sphingolipid salvage pathway in ceramide metabolism and signalingCellular Signalling, 2008
- Amide bond formation using an air-stable source of AlMe3Tetrahedron Letters, 2006
- A facile microwave-assisted palladium-catalyzed cyanation of aryl chloridesTetrahedron Letters, 2006